{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:03:44Z","timestamp":1784988224965,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,25]]},"DOI":"10.7759\/cureus.113349","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:36:46Z","timestamp":1784986606000},"source":"Crossref","is-referenced-by-count":0,"title":["Epidermal Growth Factor Receptor (EGFR) Amplification and Survival in Patients With Glioblastoma: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Maria P","family":"Fernandez Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Florez Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo de Jesus","family":"Aguirre Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Francisco","family":"Saltaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis R","family":"Moscote-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Vadivel KR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130324","article-title":"Glioblastoma: from molecular pathology to targeted treatment","volume":"9","author":"Cloughesy TF","year":"2014","unstructured":"Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014, 9:1-25. 10.1146\/annurev-pathol-011110-130324","journal-title":"Annu Rev Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak RG","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, et al.. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010, 17:98-110. 10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow JE","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, et al.. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015, 372:2499-508. 10.1056\/NEJMoa1407279","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1432-1","article-title":"Glioblastoma: pathology, molecular mechanisms and markers","volume":"129","author":"Aldape K","year":"2015","unstructured":"Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015, 129:829-48. 10.1007\/s00401-015-1432-1","journal-title":"Acta Neuropathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors","volume":"2","author":"Vivanco I","year":"2012","unstructured":"Vivanco I, Robins HI, Rohle D, et al.. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012, 2:458-71. 10.1158\/2159-8290.CD-11-0284","journal-title":"Cancer Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref9","article-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis","author":"Wells GA","year":"2014","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. Ottawa Hospital Research Institute, Ottawa (ON); 2014."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/01.pai.0000159772.73775.2e","article-title":"Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors","volume":"14","author":"Layfield LJ","year":"2006","unstructured":"Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol. 2006, 14:91-6. 10.1097\/01.pai.0000159772.73775.2e","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.4c16898","article-title":"Convection-enhanced delivery of auristatin-conjugated layer-by-layer nanoparticles for glioblastoma treatment","volume":"147","author":"Pickering AJ","year":"2025","unstructured":"Pickering AJ, Lamson NG, Marand MH, Straehla JP, Hammond PT. Convection-enhanced delivery of auristatin-conjugated layer-by-layer nanoparticles for glioblastoma treatment. J Am Chem Soc. 2025, 147:9457-71.","journal-title":"J Am Chem Soc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials","volume":"33","author":"Begley SL","year":"2025","unstructured":"Begley SL, O'Rourke DM, Binder ZA. CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials. Mol Ther. 2025, 33:2454-61. 10.1016\/j.ymthe.2025.03.004","journal-title":"Mol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cells14040254","article-title":"In vitro evaluation of genetically unmodified ligand-armed allogeneic natural killer cells to treat EGFR-positive glioblastoma","volume":"14","author":"Courot H","year":"2025","unstructured":"Courot H, Rigal E, Adib N, Criton M, Cookson A, Fauvel B, Presumey J. In vitro evaluation of genetically unmodified ligand-armed allogeneic natural killer cells to treat EGFR-positive glioblastoma. Cells. 2025, 14:254. 10.3390\/cells14040254","journal-title":"Cells"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2023.10.102","article-title":"Comparative analysis of the prognostic significance of IDH, TERT, EGFR and MGMT status in patients with adult non-H3-altered grade 4 gliomas: a prospective cohort study","volume":"181","author":"Alimohamadi M","year":"2024","unstructured":"Alimohamadi M, Larijani A, Pour-Rashidi A, et al.. Comparative analysis of the prognostic significance of IDH, TERT, EGFR and MGMT status in patients with adult non-H3-altered grade 4 gliomas: a prospective cohort study. World Neurosurg. 2024, 181:e628-39. 10.1016\/j.wneu.2023.10.102","journal-title":"World Neurosurg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03364-z","article-title":"EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?","volume":"146","author":"Armocida D","year":"2020","unstructured":"Armocida D, Pesce A, Frati A, Santoro A, Salvati M. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?. J Neurooncol. 2020, 146:275-84. 10.1007\/s11060-019-03364-z","journal-title":"J Neurooncol"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241288121","article-title":"The impact of extensive surgical resection of butterfly glioblastomas on outcomes in the presence of TERT mutation and EGFR amplification: a retrospective cohort study","volume":"31","author":"Hekimoglu M","year":"2024","unstructured":"Hekimoglu M, Basak AT, Akgun MY, et al.. The impact of extensive surgical resection of butterfly glioblastomas on outcomes in the presence of TERT mutation and EGFR amplification: a retrospective cohort study. Cancer Control. 2024, 31:10732748241288121.","journal-title":"Cancer Control"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182518e12","article-title":"Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas","volume":"36","author":"Hobbs J","year":"2012","unstructured":"Hobbs J, Nikiforova MN, Fardo DW, Bortoluzzi S, Cieply K, Hamilton RL, Horbinski C. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol. 2012, 36:1186-93. 10.1097\/PAS.0b013e3182518e12","journal-title":"Am J Surg Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5858\/2005-129-0624-GITOO","article-title":"Glioblastomas in the older old","volume":"129","author":"Kleinschmidt-DeMasters BK","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Lillehei KO, Varella-Garcia M. Glioblastomas in the older old. Arch Pathol Lab Med. 2005, 129:624-31. 10.5858\/2005-129-0624-GITOO","journal-title":"Arch Pathol Lab Med"},{"key":"ref19","article-title":"Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme","volume":"24","author":"Lopez-Gines C","year":"2005","unstructured":"Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, et al.. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin Neuropathol. 2005, 24:209-18.","journal-title":"Clin Neuropathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04879-w","article-title":"The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort","volume":"171","author":"Pulcini S","year":"2025","unstructured":"Pulcini S, Beaussire-Trouvay L, Marguet F, et al.. The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort. J Neurooncol. 2025, 171:619-28. 10.1007\/s11060-024-04879-w","journal-title":"J Neurooncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.03.051","article-title":"Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme","volume":"63","author":"Quan AL","year":"2005","unstructured":"Quan AL, Barnett GH, Lee SY, et al.. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2005, 63:695-703. 10.1016\/j.ijrobp.2005.03.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref22","article-title":"Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme","volume":"63","author":"Shinojima N","year":"2003","unstructured":"Shinojima N, Tada K, Shiraishi S, et al.. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63:6962-70.","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al.. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016, 131:803-20. 10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki H","year":"2013","unstructured":"Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013, 19:764-72. 10.1158\/1078-0432.CCR-12-3002","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1337","article-title":"Genetic pathways to glioblastoma: a population-based study","volume":"64","author":"Ohgaki H","year":"2004","unstructured":"Ohgaki H, Dessen P, Jourde B, et al.. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64:6892-9. 10.1158\/0008-5472.CAN-04-1337","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.318","article-title":"Glioblastoma, hypoxia and autophagy: a survival-prone 'm\u00e9nage-\u00e0-trois'","volume":"7","author":"Jawhari S","year":"2016","unstructured":"Jawhari S, Ratinaud MH, Verdier M. Glioblastoma, hypoxia and autophagy: a survival-prone 'm\u00e9nage-\u00e0-trois'. Cell Death Dis. 2016, 7:e2434. 10.1038\/cddis.2016.318","journal-title":"Cell Death Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1890510","article-title":"Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma","volume":"24","author":"Inda MM","year":"2010","unstructured":"Inda MM, Bonavia R, Mukasa A, et al.. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24:1731-45. 10.1101\/gad.1890510","journal-title":"Genes Dev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel AP","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, et al.. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014, 344:1396-401. 10.1126\/science.1254257","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden Y","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2:127-37. 10.1038\/35052073","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga CL","year":"2014","unstructured":"Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014, 25:282-303. 10.1016\/j.ccr.2014.02.025","journal-title":"Cancer Cell"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan CW","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, et al.. The somatic genomic landscape of glioblastoma. Cell. 2013, 155:462-77. 10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter G","year":"1990","unstructured":"Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990, 265:7709-12.","journal-title":"J Biol Chem"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a072464","article-title":"Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers","volume":"47","author":"Gullick WJ","year":"1991","unstructured":"Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991, 47:87-98. 10.1093\/oxfordjournals.bmb.a072464","journal-title":"Br Med Bull"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.111","article-title":"The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells","volume":"32","author":"Galavotti S","year":"2013","unstructured":"Galavotti S, Bartesaghi S, Faccenda D, et al.. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene. 2013, 32:699-712. 10.1038\/onc.2012.111","journal-title":"Oncogene"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.04.016","article-title":"Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells","volume":"9","author":"Catalano M","year":"2015","unstructured":"Catalano M, D'Alessandro G, Lepore F, et al.. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol. 2015, 9:1612-25. 10.1016\/j.molonc.2015.04.016","journal-title":"Mol Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24640","article-title":"Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells","volume":"229","author":"Palumbo S","year":"2014","unstructured":"Palumbo S, Tini P, Toscano M, et al.. Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells. J Cell Physiol. 2014, 229:1863-73. 10.1002\/jcp.24640","journal-title":"J Cell Physiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.287re6","article-title":"Oncogenic EGFR signaling networks in glioma","volume":"2","author":"Huang PH","year":"2009","unstructured":"Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009, 2:re6. 10.1126\/scisignal.287re6","journal-title":"Sci Signal"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00045.x","article-title":"Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas","volume":"14","author":"Biernat W","year":"2004","unstructured":"Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004, 14:131-6. 10.1111\/j.1750-3639.2004.tb00045.x","journal-title":"Brain Pathol"},{"key":"ref39","article-title":"Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo","volume":"51","author":"Ekstrand AJ","year":"1991","unstructured":"Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991, 51:2164-72.","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki H","year":"2007","unstructured":"Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007, 170:1445-53. 10.2353\/ajpath.2007.070011","journal-title":"Am J Pathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199807000-00005","article-title":"PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas","volume":"57","author":"Tohma Y","year":"1998","unstructured":"Tohma Y, Gratas C, Biernat W, et al.. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol. 1998, 57:684-9. 10.1097\/00005072-199807000-00005","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1996.tb00848.x","article-title":"Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas","volume":"6","author":"Watanabe K","year":"1996","unstructured":"Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6:217-23. 10.1111\/j.1750-3639.1996.tb00848.x","journal-title":"Brain Pathol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/60.11.1099","article-title":"Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme?","volume":"60","author":"Burger PC","year":"2001","unstructured":"Burger PC, Pearl DK, Aldape K, et al.. Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme?. J Neuropathol Exp Neurol. 2001, 60:1099-104. 10.1093\/jnen\/60.11.1099","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20625","article-title":"Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma","volume":"101","author":"Perry A","year":"2004","unstructured":"Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 2004, 101:2318-26. 10.1002\/cncr.20625","journal-title":"Cancer"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64746-3","article-title":"Genetic profile of gliosarcomas","volume":"156","author":"Reis RM","year":"2000","unstructured":"Reis RM, K\u00f6n\u00fc-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol. 2000, 156:425-32. 10.1016\/S0002-9440(10)64746-3","journal-title":"Am J Pathol"},{"key":"ref46","article-title":"Genetic profile of the giant cell glioblastoma","volume":"79","author":"Peraud A","year":"1999","unstructured":"Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H. Genetic profile of the giant cell glioblastoma. Lab Invest. 1999, 79:123-9.","journal-title":"Lab Invest"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi ME","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, et al.. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352:997-1003. 10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03358-x","article-title":"Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival","volume":"146","author":"Schaff LR","year":"2020","unstructured":"Schaff LR, Yan D, Thyparambil S, et al.. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. J Neurooncol. 2020, 146:163-70. 10.1007\/s11060-019-03358-x","journal-title":"J Neurooncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npac070","article-title":"The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients","volume":"10","author":"Torre M","year":"2023","unstructured":"Torre M, Wen PY, Iorgulescu JB. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neurooncol Pract. 2023, 10:126-31. 10.1093\/nop\/npac070","journal-title":"Neurooncol Pract"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr H","year":"2010","unstructured":"Noushmehr H, Weisenberger DJ, Diefes K, et al.. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010, 17:510-22. 10.1016\/j.ccr.2010.03.017","journal-title":"Cancer Cell"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/463662-epidermal-growth-factor-receptor-egfr-amplification-and-survival-in-patients-with-glioblastoma-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:36:53Z","timestamp":1784986613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/463662-epidermal-growth-factor-receptor-egfr-amplification-and-survival-in-patients-with-glioblastoma-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.113349","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}